Loading...
Loading...
IMNM| Name | Value |
|---|---|
| Revenues | 2,364.0K |
| Cost of Revenue | 148.0K |
| Gross Profit | 2,216.0K |
| Operating Expense | 6,835.0K |
| Operating I/L | -4,471.0K |
| Other Income/Expense | 201.0K |
| Interest Income | 201.0K |
| Pretax | -4,270.0K |
| Income Tax Expense | -201.0K |
| Net Income/Loss | -4,069.0K |
Immunome, Inc. is a biopharmaceutical company specializing in the discovery and development of antibody therapeutics for oncology and infectious diseases. The company's lead oncology program, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint to combat immune system evasion. Additionally, Immunome, Inc. is developing IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
